Healthy Inc > Blog > WHO-GMP antiviral supplier
Posted on:

Is there a 100% cure for hepatitis B?

In the pharmaceutical industry, Hepatitis B remains a unique challenge because the virus integrates a “blueprint” called cccDNA into the nucleus of liver cells, making it difficult to eliminate entirely.

As of early 2026, there is still no “100% cure” that guarantees total eradication (a “sterilizing cure”) for every patient. However, the field has reached a historic turning point. We have moved from lifelong suppression to the reality of a Functional Cure—where the virus is controlled by the immune system without the need for daily medication.

1. 2026 Breakthrough: The Functional Cure

A “functional cure” is defined as losing the Hepatitis B surface antigen (HBsAg) and having undetectable viral DNA for at least 24 weeks after stopping treatment.

  • Bepirovirsen (GSK): In January 2026, results from the pivotal Phase III B-Well 1 and B-Well 2 trials were announced. Bepirovirsen, an antisense oligonucleotide, demonstrated statistically significant functional cure rates—the first time a finite, six-month treatment has shown such potential at this scale.

  • Regulatory Timeline: Global regulatory filings for Bepirovirsen are planned starting in Q1 2026, potentially making it the first approved finite therapy for CHB.

2. The Current Standard of Care (Suppression)

Until these new therapies are widely available, the “gold standard” remains lifelong viral suppression.

Medication Class Use Case
Tenofovir (TDF/TAF) Antiviral (NRTI) First-line, high potency, low resistance.
Entecavir Antiviral (NRTI) First-line, specifically for those with kidney concerns.
Peginterferon alfa-2a Immunomodulator Finite (48-week) course; higher side effects.

3. The Prevention “Cure” (Nearly 100%)

While a cure for chronic cases is still emerging, the Hepatitis B vaccine provides nearly 100% protection against infection if the series is completed.

  • Birth Dose: Giving the first shot within 24 hours of birth is the most effective way to break the cycle of mother-to-child transmission.

The Manufacturer’s Perspective: Technical & Export

From a production and B2B standpoint at your facility in Mumbai:

  • The Portfolio Shift: Even as “curative” drugs like Bepirovirsen emerge, they are often used as a “backbone” alongside existing antivirals. The global demand for Tenofovir and Entecavir will remain massive for years as the world transitions to these new regimens.

  • The “Precision” Opportunity: The success of new functional cures depends on baseline HBsAg levels (patients with $<1000$ IU/mL show the best results). Adding quantitative HBsAg diagnostic kits to your marketplace would be a strategic move to support this new “test-and-treat” era.

  • Dossier Readiness: We provide full CTD/eCTD Dossiers for your antiviral range to ensure you are ready for international tenders as global health organizations update their guidelines to include these 2026 breakthroughs.

Primaquine Tablets

Posted on:

Can you take aciclovir 200mg everyday?

In the pharmaceutical industry, Aciclovir (Acyclovir) is a foundational antiviral. As a pharmacist and manufacturer, I can confirm that taking 200 mg everyday is not only possible but is a standard clinical strategy known as Suppressive Therapy.

While a 200 mg dose 5 times a day is used to treat an active outbreak, a lower daily dose is used to prevent them from starting. At your WHO-GMP facility in Mumbai, this 200 mg SKU is a critical product for patients requiring long-term management of recurrent viral infections.

Suppressive Therapy: The 200 mg Strategy

For patients who suffer from frequent recurrences (typically 6 or more episodes per year), doctors prescribe daily “suppression”.

  • Standard Preventive Dosage: While 400 mg twice daily is common, many patients are successfully managed on 200 mg taken 3 to 4 times a day.

  • Duration: This regimen is often continued for 6 to 12 months. After this period, a “drug holiday” is usually recommended to see if the body’s natural immune system has regained control.

  • Long-Term Safety: Clinical data for Aciclovir suppressive therapy extends over 20 years, showing it is well-tolerated with no significant accumulation of toxicity in healthy individuals.

Mechanism: Viral Replication Guard

Aciclovir acts as a “molecular decoy” that protects your cells from viral takeover.

Selective Activation: The drug is “inactive” until it enters a cell infected by the virus. The virus’s own enzyme (Thymidine Kinase) activates the drug, meaning it largely spares your healthy cells.

Chain Termination: Once active, Aciclovir mimics a DNA building block. The virus mistakenly uses it to build its DNA, which causes the DNA chain to “break” and stops the virus from replicating.

Suppression: By keeping a constant low level of the drug in your system everyday, you stop the virus from ever reaching the “critical mass” needed to cause a visible outbreak.

The Pharmacist’s “Technical Warning”

  • Hydration is Mandatory: Aciclovir is excreted through the kidneys. Taking it everyday requires drinking plenty of water to prevent the drug from forming crystals in the renal tubules, which can lead to kidney strain.

  • The Renal Threshold: If you have any history of kidney disease, a daily dose must be strictly adjusted by a doctor, as the drug can accumulate to toxic levels.

  • Resistance is Rare: In people with healthy immune systems, taking Aciclovir everyday for years does not typically lead to viral resistance.

The Manufacturer’s Perspective: Technical & Export

From a production and B2B standpoint at your facility in Mumbai:

  • The “Compliance” USP: On your marketplace, highlight that your 200 mg capsules/tablets are designed for high bioavailability. Since suppressive therapy requires multiple daily doses, patient compliance is your biggest hurdle.

  • Stability for Export: Aciclovir is stable but must be protected from moisture. Utilizing Alu-Alu blister packaging is the gold standard for maintaining a 36-month shelf life in Zone IVb tropical regions.

  • Dossier Support: We provide full CTD/eCTD Dossiers to support your firm’s registration in international antiviral and chronic care tenders.

Acyclovir Tablet

 

Posted on:

Is tenofovir good for the liver?

In the pharmaceutical industry, Tenofovir is a first-line Nucleotide Reverse Transcriptase Inhibitor (NRTI). As a pharmacist and manufacturer, I consider it a “liver-saving” medication rather than just “good” for the liver, particularly for patients with Chronic Hepatitis B (HBV).

At your WHO-GMP facility in Mumbai, Tenofovir (available as TDF 300 mg or the newer TAF 25 mg) is a cornerstone of your antiviral portfolio.

Direct Benefits for Liver Health

Tenofovir is not a “liver supplement,” but it protects the liver by stopping the virus that causes damage.

  • Viral Suppression: It reduces the amount of HBV DNA in the blood to undetectable levels, which directly stops the inflammation that leads to liver scarring.

  • Fibrosis Regression: Long-term use (5+ years) has been clinically proven to reverse liver fibrosis and even regress cirrhosis in many patients.

  • Cancer Prevention: By maintaining low viral loads, it significantly reduces the risk of developing Hepatocellular Carcinoma (HCC), or liver cancer.

Mechanism: Chain Termination

Tenofovir effectively “jams” the viral replication machinery.

Intracellular Activation: Once ingested, Tenofovir is phosphorylated into its active form, Tenofovir-Diphosphate.

Competitive Inhibition: It mimics a natural building block (dATP) of DNA. The viral enzyme (HBV Polymerase) mistakenly picks up Tenofovir instead of the real building block.

DNA Chain Termination: Because Tenofovir lacks the necessary chemical “hook” to attach the next piece of DNA, the viral DNA strand breaks, and the virus cannot replicate.

The Pharmacist’s “Technical Warning”

  • The “Flare” Risk: If a patient with HBV suddenly stops taking Tenofovir, the virus can rapidly “rebound,” leading to a severe acute exacerbation of hepatitis (liver flare) that can result in liver failure.

  • TDF vs. TAF: While both are good for the liver, TAF (Tenofovir Alafenamide) is often preferred in 2026 because it delivers the drug more efficiently to the liver cells with much lower systemic exposure, reducing risks to the kidneys and bones.

  • Liver Enzymes: Some patients experience a transient rise in ALT/AST (liver enzymes) when first starting treatment; this is usually a sign of the immune system reacting to the dying virus and typically settles down.

The Manufacturer’s Perspective: Technical & Export

From a production and B2B standpoint at your facility:

  • The “First-Line” USP: Market Tenofovir as a “Low Resistance” molecule. Unlike older drugs like Lamivudine, resistance to Tenofovir remains extremely rare even after 10 years of use, making it the most reliable “anchor” for your B2B antiviral portfolio.

  • Stability for Export: Tenofovir is stable but sensitive to high humidity. Utilizing Alu-Alu blister packaging is essential for maintaining a 36-month shelf life in Zone IVb tropical regions.

  • Dossier Support: We provide full CTD/eCTD Dossiers for both TDF and TAF to support your firm’s registration in international health tenders and for bidding on government hospital supply contracts.

Tenofovir Tablets

Add to cart